EP3746037A1 - Stable wound healing ointment - Google Patents

Abstract

The invention relates to a stable cosmetic or dermatological formulation, in particular a wound healing ointment, which contains a.) 0.8 to 3 wt.-%, in particular 1.2 to 1.8 wt.-% glyceryl stearates, b.) 0.8 to 3 wt.-%, in particular 1.2 to 1.8 wt.-% glyceryl stearates SE, c.) one or more lipids selected from the group including ceresin, cera microcristallina and paraffinum liquidum, advantageously 8 to 12 wt.-%, in particular 9 to 11 wt.-% ceresin, d.) less than 1 wt.-% water, and e.) less than 0.1 wt.-% of each of cholesterol and lanolin alcohol.

Description

 Stable wound ointment

 The invention is a cosmetic or dermatological formulation, in particular a wound healing ointment, comprising two specific emulsifiers in certain proportions and one or more lipids selected from the group Ceresin, Cera Microcristallina and Paraffinum Liquidum, preference being given to components of animal origin being dispensed with as far as possible.

From wound healing ointments, pastes and hydrogels, such as Bepanthen © Wundheilsalbe, Aquaphor® or Fenistil ® are known.

A consumer demand is increasingly to dispense with substances of animal origin in cosmetics.

However, in particular the stability criteria should continue to be met.

The present invention therefore has as its object to provide a stable ointment formulation

 Problems of the prior art ointment bases are:

 the appearance changes with time

 • often yellowish-orange-brownish tint, shiny, somewhat translucent Stability loss:

 • Consistency increase over the lifetime

 At higher temperatures, e.g. 40 ° C, a significant Ausölung occurs

• At higher temperatures (40 ° C) and under the influence of light, clear discoloration turns towards dark orange-brown

 • The odor deteriorates significantly at higher temperatures and under the influence of light

These disadvantages should be avoided or reduced.

 The problems are solved by a cosmetic or dermatological preparation comprising

 a.) 0.8 to 3 wt.%, In particular 1, 2 to 1, 8 wt.% Glyceryl stearates,

 b.) from 0.8 to 3% by weight, in particular from 1.2 to 1.8% by weight, of glyceryl stearate SE,

 c.) one or more lipids selected from the group Ceresin, Cera Microcristallina and

Paraffin Liquidum d.) Less than 1 wt.% Water and

 e.) less than 0.1 wt.% of each cholesterol and lanolin alcohol.

 The parts by weight are based on the total weight of the preparation.

 Advantageously, the preparation of the invention comprises 8 to 15 wt.%, In particular 9 to 12 wt.% Ceresin, based on the total mass of the preparation.

 Advantage of the preparation according to the invention is that a large regulatory

Freedom of formulation is given because on the one hand no ingredients of animal origin are to be used but on the other hand further additives can be added without achieving stability problems.

 The approach of not using ingredients of animal origin is to exclude killed animal or derived products.

 In the absence of ingredients of animal origin, it is particularly important to abstain from lanolin alcohol and cholesterol.

 Lanolin alcohols consist of the highly refined, unsaponifiable portion of wool wax, which was subsequently subjected to molecular distillation to improve color and odor. Lanolin alcohols are a very complex mixture of alcohols with an average molecular weight of about 370 Da, consisting of cholesterol, lanosterol,

Agnosterol and its dihydro derivatives as well as straight and branched chain aliphatic alcohols. In addition to nourishing properties, they have excellent W / O emulsifying ability, which is why they have been used in many cosmetics.

 In cosmetic preparations, purified wool wax is used as a co-emulsifier, strongly adhering lipid and superfatting agent. Lanolin, as an alternative to petrolatum, can be used as a nasal ointment for the care of the mucous membranes.

 Wool wax (also called lanolin, wool fat, lat. Adeps lanae) is the secretion from the sebaceous glands of sheep, which is obtained in the washing of sheep's wool.

Cholesterol is one of the non-ionic emulsifiers and is used primarily as an emulsifier and stabilizer for emulsions of oil and water in various fields.

The cosmetics industry uses the substance for some cosmetics in their function as emollient, emulsifying, skin care, stabilizing and

Viscosity regulating ingredient for ointments and creams.

In addition, the chemical serves to synthesize derived compounds,

in particular cholesteryl esters, which are also processed in cosmetic products However, commercially traded and used cholesterol still comes from natural sources. For the production of the pure chemical primarily the spinal cord of cattle and the wool fat (lanolin) of the sheep are used. The

Production is usually carried out by extraction with petroleum ether. The extracted material is then purified by repeated bromination.

 According to the invention, the addition of these substances of animal origin is dispensed with.

 The proportion of cholesterol and lanolin alcohol is therefore in each case less than 0.1% by weight, in particular 0% by weight, based on the total mass of the preparation. That the proportion of a maximum of 0.1% of these substances guaranteed if impurities Lanolinalkohole or cholesterol have been entrained with.

 The formulation of the invention is ideally anhydrous. However, because of impurities, by additives such as glycerol, in the manufacturing process-based entrainment or during storage, water may be added, the proportion of water is less than 1 wt.% To choose, in particular less than 0.1 wt.%, Based on the total mass of the formulation to be considered "anhydrous". An anhydrous formulation according to the invention applies if its water content is less than 1% by weight, in particular less than 0.1% by weight, based on the total mass of the preparation.

 According to the invention, the cosmetic or dermatological preparations comprise glyceryl stearate and glyceryl stearate SE.

 Investigations have shown that this combination surprisingly provides the required stability.

 Glyceryl stearate SE (CAS 11099-07-3) and glyceryl stearates (CAS 31566-31-1) are esters of stearic acid and glycerol.

Glyceryl Stearate SE is a self-emulsifying variant of glyceryl stearate and includes sodium and potassium stearates.

Glycerol stearate SE is a combination of mono- and diglycerides from vegetable oils and about 3 percent potassium stearate. The addition "SE" describes the self-emulsifying form of glycerine stearate, which is achieved by potassium stearate (potassium soap).

 According to the invention, the proportion of glyceryl stearate and glyceryl stearate SE in each case in the range of 0.8 to 3 wt.%, In particular 1, 2 to 1, 8 wt.%, Based on the

Total mass of the preparation chosen.

The lipid ceresin (CAS 8001-75-0) also called ceresin, cerosin, cerin, ground wax, mineral wax, ozocerotine or artificial wax) is heated by adding 6 to 10% sulfuric acid made from ozokerite - an organic mineral derived from mining and consisting essentially of hydrocarbons.

The formulations preferred according to the invention comprise highly viscous lipid-containing preparations.

High viscosity liquids such as honey or syrup have dynamic viscosities at 25 ° C of more than 10,000 mPa ^* s.

The lipid-containing preparation preferably has a dynamic viscosity of more than 10,000 mPa ^* s at 25 ° C. and a shear rate of 10 s ^-1 . In particular, the lipid-containing preparation has a dynamic viscosity in the range of 15,000 to 30,000 mPa ^* s, in particular in the range of 18,000 to 25,000 mPa ^* s at 25 ° C and a shear rate of 10 s ¹ (measuring device Brookfield rotary viscometer Disk spindle 2).

 Viscosity is the measure of the internal friction of liquids, a measure of the viscosity of a fluid. The reciprocal of the viscosity is the fluidity, a measure of the fluidity of a fluid. The higher (or higher) the viscosity is, the better

viscous, i. The less fluid the fluid is, the lower the viscosity, the thinner it is, and the higher the fluidity.

 There is a distinction between dynamic and kinematic viscosity. The dynamic viscosity is given in Pa s (pascal second) and usually using a

Rotational viscometer determined. The kinematic viscosity is measured in m ² / s. It indicates the internal friction of a liquid and is calculated by dividing the dynamic viscosity by the density of a liquid.

 The consistency, in turn, is the resistance of a substance to its deformation.

 The preparation according to the invention is advantageously formulated as an ointment. As ointment (lat.

Unguentum) or cream according to the invention is understood to mean a semi-solid and advantageously homogeneous-looking preparation intended for use on the skin (for example as an ointment for ointment) or on the mucous membranes. Ointments are for the local application of active ingredients or the care and protection of the skin, wounds or mucous membranes.

It consists primarily of a greasy base of natural or synthetic substances and may be a single-phase (eg Ceresin, Cera Microcristallina and / or Paraffinum liquidum) or multi-phase system. Active ingredients or drugs may be incorporated in solution or dispersion in the ointment or cream. The release of active ingredients from the ointment is possible and preferred according to the invention. In the meaning of the invention include the term ointment

Ointments in a narrower sense, single phase,

 • creams,

 • gels, lotions and

 • pastes

 Ointment according to the invention, which is particularly preferably anhydrous, comprises in particular all three preferred lipids, Ceresin, Cera Microcristallina and Paraffinum liquidum.

 Active ingredients may be contained in the ointment or cream. Active ingredients are in particular natural additives.

 Likewise, the use of at least one active ingredient is selected from the

anti-inflammatory or wound healing promoting agents for local

Pain relief and anti-inflammatory a particularly preferred application.

Advantageously, moreover, the use of at least one active substance selected from the group of antiseptics, antibiotics or antimycotics for local wound disinfection and / or reduction of germ colonization has been found.

 Advantageously, the preparation may contain anti-inflammatory, wound healing stimulating, analgesic or antimicrobial agents.

 For example, the preparation can be antiinflammatory or wound healing promoting agents such as zinc acetate 2H2O, zinc sulfate 7H2O, allantoin, aloe vera, arnica, bisabolol, calendula, chamomilae, dexpanthenol, enzyme inhibitors, hamamelis, urea, honey / manuka honey, hyaluronic acid, St. John's wort, chamomile extract, polidocanol, propolis, Vitamins or provitamins, growth factors, eg PDGF, wheat germ extract, zinc oxide, vitamin A, vitamin C, vitamin E, chitosan capsicum annuum L. and derivatives, benzydamine, benzyl nicotinate, bufexamac, diclofenac, etofenamate, flufenamic acid, heparinoids ibuprofen, indomethacin, ketoprofen, naxoprophen, piroxicam, salicylic acid and their derivatives , Teniposide, 2-hydroxybenzoic acid, acetylsalicylic acid and derivatives, Acid. silicicum D8, aconitum (monkshood), aconitum D3, aescin (horse chestnut), D4 ("dog parsley"), ammonium bituminosulfonate (ICHTHYOL®), Arnica D3, Arnica mont. D4, Arnica montana ex herba rec. ad usum ext, extract of guaiac wood, extract of Arnica montana, Baisamum peruvianum (Peru balsam), Comfrey root fluid extract, Benzyl nicotinate, Calendula ad ext. ext., Calendula D3, Calendula 0, Calendula offic. D3, Calendula officinalis 0, Camphor, Chamomilla, Colchicum e seminibus D4, Conium D2, Cort. Heisteriae, Cort. Salicis, D-camphor, Delphinium staph (Stefanskörner), Delphinium staph. D4, dexpanthenol,

Diclofenac diethylamine, diclofenac sodium, diethylazan salt, dimethyl sulfoxide, echinacea ang., Echinacea 0, Echinacea purp., Echinacea purp. 0, Echinacea purpurea, Planta tota 0, Goldenrod Common Rod, Etofenamate, Extr. Flor Calendulae spiss, Extr. Fol Digitalis fluid, Extr. Fol Hyoscyami fluid, Extr. Herba Conii maculate, Extr. Rad. Petasit. Spiss, Extr. Rhiz.

Podophylli fluid., Extr. Semen Colchici fluid, Ferrum phosphoricum D10, Spruce needle oil, Flufenamic acid, Fol. Betulae, Guaiacum 0 (guaiac), Guaiac wood dry extract, Hamamelis D4 ("witch hazel"), Harpagophytum procumbens, Helianthus ann. D4, Hepar sulf. D8, Hepar sulfuris, heparin sodium, humic acids, hydroxyethyl salicylate, hypericum, ibuprofen, indomethacin, isobornyl acetate, potassium bichrom. D8, potassium sulf. D8, potassium iron phosphate-citrate complex, ketoprofen, Lachesis mutus D8, mountain pine oil, Levisticum,

Wheel. Sicc. H 10%, Levomenthol, Mercurialis perennis 2b 0, Mercurius bijodatus D5,

 Mercurius solub. Hahnem, Mercurius solub. Hahnem. D8, methyl nicotinate, methyl salicylate (salicylic acid methyl ester), millefolium, myrtainaine, naloxone HCl, sodium thiosulfate, nat. Eifelfango, Nicoboxil, Paracetamol, PI. Tota rec, quartz, Rad. Harpagophyti (devil's claw), Rad. Harpagophytum procumbens, Resina Laricis (Terebinthina laricina), Rhus

Toxicodendron D6, Ruta D6 (rue), salicylic acid, sulfur, Stibium metallicum praeparatum, Stibium sulfuratum nigrum D1, Symphytum (comfrey), Symphytum D6, Symphytum offic. e rad. D6, Devil's Claw Root Extract, Tilidine HCI 0.5H ₂ O,

 Tilidine phosphate, toxin of Vipera ammodytes, tramadol HCl, extract of nettle leaves, extract of horse chestnut seed, extract of willow bark, extracts of aspen bark and leaves and / or triclosan.

 Particularly preferred are panthenol (dexpanthenol), allantoin, bisabolol, urea, honey, e.g. Manuka honey, hyaluronic acid, licochalcone, in particular licochalcone A, polidocanol, propolis, zinc oxide, vitamins and / or provitamins such as e.g. Vitamin A, C or E contained in the preparation.

 Derivatives as well as related and similar substances, also in combination or in combination with other substances may also be included. Aloe vera, calendula, chamomile,

 Witch hazel, St. John's wort, wheat germ, eucalyptus and their extracts or

Active substance combinations with these substances can also be included. Other possible wound healing promoting agents are other herbal wound healing substances or substance mixtures or plant extracts. The use of one or a combination of the listed substances promote moist wound healing.

 Very particular preference is given to panthenol, bisabolol, licochalcone A, polidocanol.

 These substances can advantageously be used in a proportion of 0.05 to 5 wt.% In the preparation, preferably in a proportion of 0.1 to 3 wt.%, In particular from 0.5 to 2.5 wt.%, Based on the total mass of the preparation.

Zinc oxide is also particularly preferred and may contain from 0.05 to 20% by weight. are used in the preparation, preferably in a proportion of 0.1 to 10 wt.%, In particular from 0.5 to 5 wt.%, Based on the total mass of the preparation.

 Other possible active ingredients included in the preparation are local anesthetics that are suitable for surface anesthesia, e.g. Arsenicum album D12 (white arsenic), Articaine, Articaine HCl with epinephrine HCl, Atropium sulf. D5, benzalkonium chloride,

 Benzocaine, bupivacaine, bupiviacin HCl, chloroethane, cinchocaine, dibucaine, etidocaine, fomocaine, Formica rufa D12 (red wood ant), Hypericum perf. D5, lidocaine, lidocaine HCl, mepivacaine, mepivacaine HCl, methyl 4-hydroxybenzoate, oxybuprocaine, oxybuprocaine HCl, prilocaine, procaine, procaine HCl, procaine HCl with caffeine, propyl 4-hydroxybenzoate,

Quinisocaine, ropivacaine, ropivacaine HCl, sulfur D12, tetracaine, tetracaine HCl with

Macrogollauryl ethers and / or Liquorize extracts.

 Especially beneficial agents for local pain relief such as

Example benzocaine, procaine, lidocaine or prilocaine be included in the preparation.

 The use of local anesthetics provides an additional benefit of a fast

Pain relief of an injured skin site. Local anesthetics can be used in a proportion of 0.01 to 4 wt.% In the preparation, preferably in a proportion of 0.05 to 3 wt.%, In particular from 0.5 to 2.5 wt.%, Based on the Total mass of the preparation.

 Further particularly advantageous active ingredients are cyclooxygenase inhibitors

Pain relief and anti-inflammatory, such as acetylsalicylic acid or non-steroidal anti-inflammatory drug (NSAIDs) such as diclofenac, ibuprofen,

Ketoprofen, benzydamine, benzyl nicotinate, bufexamac, etofenamate, flufenamic acid, heparinoids, naxoprophene, piroxicam, teniposide or indomethacin. Their derivatives as well as related and similar substances also in combination or in combination with other substances can be contained in the preparation for an additional

To provide pain relief effect. Cyclooxygenase inhibitors may be present in a proportion of 0.01 to 10 wt.%, Preferably in a proportion of 0.1 to 5% and particularly preferably in a proportion of 0.2 to 2.5%. Herbal painkillers such as Aescin, Guaiac wood, Rhiz. Podophylli, Herba Conii, Fol Hyoscyami, Fol Digitalis, Echinacea purpurea, Ash Bark, Delphinium staph, Camphor, Baisamum Peruvianum, Comfrey root, Goldenrod, and Aethusa, and extracts and combinations thereof may also be included as very beneficial in the preparation, advantageously at a level of 0.1 to 5 wt.%, Particularly advantageous to a proportion of 0.5 to 3 wt.%, Based on the total mass of the preparation. The preparation may also contain antiseptic, antibiotic or antifungal agents. An antiseptic action prevents infections of the wound and thereby offers an additional benefit of the formulation according to the invention.

 Antiseptic, antibiotic and antifungal / antifungal agents, including aminoglycosides, prevent infection by preventing the growth of microorganisms. Antimicrobial metals, for example silver, or their salts, chlorhexidine, octenidine hydrochloride, polyhexanide, povidone-iodine, taurolidine, 2,2'-methylenebis (6-bromo-4-chlorophenol), 2-biphenylol (instruments), may be mentioned as advantageous. 3,5-Dibromo-4-hydroxybenzenesulfonic acid, 5-chloro-2-hydroxybenzoic acid, aluminum acetate tartrate, benzalkonium chloride, benzyl alcohol, biphenyl-2-ol, Clorofen, butane-1, 3-diol, quinoline-8-olsulfate, quinolinol sulfate Potassium sulfate, chlorhexidine bis (D-gluconate),

Chlorhexidine digluconate, cocospropylenediamine, didecyldimethylammonium chloride,

Ethacridine lactate I H2O, glucoprotamine, glutaral, potassium thiocyanate, meconium acetyl sulfate, methyl 4-hydroxybenzoate, octenidine-2HCl, phenoxyethanol, polyhexanide, povidone-iodine, propyl-4-hydroxybenzoate, tosylchloramide-sodium 3H2O, undecylenic acid,

Hydrogen peroxide, bifonazole, ammonium bituminosulfonate, bacitracin, benzoyl peroxide, quinoline-8-olsulfate, chloramphenicol, chlortetracycline HCl, clindamycin, clindamycin-2-dihydrogen phosphate, clioquinol, erythromycin, framycetin sulfate (neomycin B), fusidic acid 0.5H ₂ O, gentamycin sulfate, purified Turpentine oil, imiquimod, isotretinoin, larch terpentin, meclcycline (5-sulfo-2-hydroxybenzoate), metronidazole miconazole nitrate, mupirocin, nadifloxacin, sodium bituminosulfonate (ICHTHYOLO sodium), sodium fusidate,

Neomycin sulfate, oxytetracycline HCl, podophyllotoxin, retapamulin, sulfadiazine silver, tetracycline HCl, tretinoin, dry extract of lemon balm leaves, tyrothricin. Particularly advantageous chitosan, chlorhexidine, povidone-iodine, silver or sulfadizine silver, triclosan, octenidine hydrochloride, polyhexanide, taurolidine or fungicides may be included.

 Derivatives, similar substances and combinations thereof are therefore also included according to the invention. Herbal antiseptics such as purified turpentine or larch turpentine may also be included as active ingredients in the formulation.

 Particular preference is given to the antiseptic agents silver and its salts, octinidine and its derivatives, in particular octenidine dihydrochloride (octinidine and its derivatives also in combination with phenoxyethanol), iodine and its derivatives, povidone-iodine, polihexanide and its derivatives, especially polihexanide hydrochloride, chlorhexidine and its derivatives, in particular chloride and acetate, in particular chlorhexidine digluconate.

Antiseptic agents may be present in a proportion of 0.1 to 10% by weight in the preparation, preferably in a proportion of 0.5 to 3% by weight, preferably in a proportion of 0.5 to 5% by weight on the total mass of the preparation. More antiseptic Active ingredients such as ethacridine lactate can be contained in a proportion of 0.05 to 1 wt.%, Advantageously in a proportion of 0.1 to 0.5 wt.%.

 Ketoconazole, micronazole, ciclopirox (or its ethanolamine salt ciclopiroxolamine), amorolfine and its derivatives, naftifine, pyrroline nitrite, terbinafine, bifonazole and / or clotrimazole are particularly preferred for the antifungal agents.

 Antimycotic agents may be present in a proportion of 0.1 to 10 wt.% In the preparation, preferably in a proportion of 0.5 to 3 wt.%, Preferably in a proportion of 0.5 to 5 wt.%, Based on the total mass of the preparation.

 Active ingredients for faster healing of cold sores can be particularly preferably contained in the preparation. Examples are heparin sodium, foscarnet sodium, tromantadine, idoxuridine, dimethyl sulfoxide, pencicolvir and acyclovir. In addition to moist wound healing, a virustatic active ingredient offers an additional effect for a faster healing of herpes vesicle outbreaks. Antivirals may advantageously be present in a proportion of 1 to 10% by weight, preferably in a proportion of 3 to 8% by weight. Herbal antivirals such as e.g. Extracts of melissa leaves may be present in a proportion of 1 to 20% by weight, advantageously in a proportion of 5 to 15% by weight.

 It is particularly preferred that cosmetic skin-care active ingredients are contained in the preparation.

 The following active ingredients may advantageously be included, selected from the group of

Compounds glycerol, panthenol, bisabolol, glycyrrhetinic acid, urea, arctiin, alpha-lipoic acid, folic acid, phytoene, D-biotin, coenzyme Q10, alpha-glucosylrutin, tocopheryl acetate, carnitine, carnosine, caffeine, natural and / or synthetic isoflavonoids, glycerylglucose, Creatine, creatinine, taurine, magnolia, b-alanine and / or licochalcone A.

The active ingredient (s) are advantageously present in a proportion of 0.001-10% by weight, preferably 0.01-5% by weight, more preferably 0.05-1% by weight, preferably 0.01-0.5% by weight, based on the total mass of the preparation.

 In a particularly preferred embodiment, the preparations according to the present invention contain so-called moisturizers. As a moisturizer, substances or

Mixtures of substances which give cosmetic preparations the property of reducing the moisturization of the horny layer (also called transepidermal water loss (TEWL) after application or spreading on the skin surface and / or positively influencing the hydration of the horny layer.

Advantageous moisturizers for the purposes of the present invention are, for example, glycerol, lactic acid and / or lactates. More preferred skin moisturizers are in particular Sodium lactate, Butylene glycol, Propylene glycol, Biosaccaride gum-1, Glycine soy,

Ethylhexyloxyglycerol, pyrrolidonecarboxylic acid, urea, glyceryl glucosides.

 The amount of moisturizers, one or more compounds, is advantageously from 1 to 20% by weight, preferably from 3 to 15% by weight, particularly preferably from 5 to 12% by weight, based in each case on the total weight of the preparation, selected.

 In addition to the preferably mentioned lipids Ceresin, Cera Microcristallina and / or Paraffinum Liquidum, in particular Ceresin, the preparation according to the invention preferably comprises further lipids, such as waxes from the group of fats, in particular from the group of natural waxes. The preparation preferably comprises one or more lipids selected from the group

 Shorea Stenoptera Seed Butter, Hydrogenated Vegetable Oil, Hydrogenated Coco-Glycerides, Butyrospermum Parkii Butter, Theobroma Cacao (Cocoa) Seed Butter, Mango Butter, Hydrogenated Palm Kernel Glycerides, Hydrogenated Palm Glycerides, Sunflower Seed Wax, Soybean Glycerides, Butyrospermum Parkii Unsaponifiables, Cera Alba, Beeswax, Sugar Cane Wax, Cera Carnauba, Candelilla Wax, Japan Wax, Hydrogenated Rapeseed Oil, Shellac Wax, Hydrogenated Lecithin, Hydrogenated Soybean Oil, from the group of synthetic waxes, in particular

 Synthetic Beeswax, Synthetic Wax, Polyethylene, Paraffin Wax, Ozokerite

from the group of fatty acids, in particular

 Palmitic Acid, Stearic Acid,

from the group of esters of fatty acids, in particular

 Cetearyl Nonanoates, Methyl Palmitates, Glyceryl Tribehenates, Glyceryl Laurates, Glyceryl Stearates, Cetyl Palmitates; Shea Butter Oleyl Esters, PEG-8 Beeswax.

The preparation according to the invention preferably comprises Cera Microcristallina.

 Furthermore, the lipid phase may also advantageously contain non-polar oils, for example those which are selected from the group of branched and unbranched hydrocarbons, in particular mineral oil, Vaseline (petrolatum), paraffin oil, squalane and squalene, polyolefins, hydrogenated polyisobutenes and isohexadecane. Among the

Polyolefins are polydecenes the preferred substances.

Preference is given to choosing natural oil, vegetable oil or mineral oil, in particular paraffin liquidum. The total amount of lipids, in particular Ceresin, Cera Microcristallina and Paraffinum Liquidum, is selected to a proportion of more than 50 wt.% Up to a proportion of 90 wt.%, In particular in the range of 75 to 85 wt.%, Based on the Total mass of the preparation. If ceresin is present, its proportion is advantageously selected in the range from 8 to 15% by weight, based on the total mass of the preparation.

 The cosmetic or dermatological formulations according to the invention may further contain cosmetic adjuvants and active ingredients such as are commonly used in such formulations, e.g. As preservatives, preservatives, bactericides, substances for preventing foaming, dyes and color pigments, thickeners, moisturizing and / or moisturizing substances, anti-aging substances or other conventional ingredients of a cosmetic or dermatological formulation such as polyols, polymers, provided that the additive required properties in terms of stability, sensor technology, care effects, freedom from water and freedom from substances of animal origin are not impaired.

 The cosmetic compositions according to the present invention, depending on their structure, for example, be used as Wundheilsalbe, skin protection cream, nutritional cream, day or night cream.

 The preparation according to the invention is preferably to be used as a non-therapeutic skin ointment

 Also preferred is the use of the preparation as a wound healing ointment, in particular as a non-therapeutic wound healing ointment.

 The following example illustrates the formulations according to the invention.

 Unless otherwise indicated, the figures relate to parts by weight based on the total mass of the preparation.

 Stability sensors and haptics tests were performed with this formulation.

Only the use of a mixture of the two emulsifiers glyceryl stearate and glyceryl stearate SE showed that this preparation was stable and, at the same time, much more appealing in terms of sensor technology and electroplating.

 In terms of stability, in particular good results were found in the combination of 1, 5 wt.% Glycerylstearat and 1, 5 wt.% Glycerylstearat SE and 15 wt.% Ceresin. No oiling was observed. The combination 1, 5 wt.% Glycerylstearat and 1, 5 wt.% Glycerylstearat SE and 10 wt.% Ceresin also showed no Ausölung. However, the ointment was softer in consistency and therefore more pleasant in terms of feel and feel. Thus, a preparation comprising ceresin in a proportion of 8 to 12 wt.%, In particular 10 wt.%, Based on the total mass of the preparation, particularly preferred.

Claims

claims

 1. Cosmetic or dermatological preparation comprising

 a.) 0.8 to 3 wt.%, In particular 1, 2 to 1, 8 wt.%, Glyceryl stearates,

 b.) from 0.8 to 3% by weight, in particular from 1.2 to 1.8% by weight, of glyceryl stearate SE,

 c.) one or more lipids selected from the group Ceresin, Cera Microcristallina and

Paraffin Liquidum,

 d.) Less than 1 wt.% Water and

 e.) Less than 0.1% by weight of each cholesterol and lanolin alcohol,

 wherein the weight fractions are each based on the total mass of the preparation.

2. Preparation according to claim 1 comprising

 c.) 8 to 15 wt.%, In particular 9 to 12 wt.%, Ceresin.

3. Preparation according to one of the preceding claims, characterized in that the preparation has a dynamic viscosity of more than 10 000 mPa ^* s at 25 ° C and a shear rate of 10 s ^-1 , in particular a dynamic viscosity in the range of 15,000 to 30 000 mPa ^* s, especially in the range of 18 000 to 25 000 mPa ^* s.

4. Preparation according to one of the preceding claims, characterized in that

 additionally one or more wound-healing-promoting active substances, in particular panthenol, and one or more skin moisturizing agents, in particular glycerol, are contained.

5. Preparation according to one of the preceding claims, characterized in that the total proportion of lipids in the range of more than 50 wt.% Up to 90 wt.%, In particular in the range of 75 to 85 wt.%, Is selected, based on the

 Total mass of the preparation.

6. Use of the preparation according to one of the preceding claims as a non-therapeutic skin ointment.